Arnd Christ
Director of Finance/CFO at IMMATICS N.V.
Net worth: 2 M $ as of 30/03/2024
Profile
Arnd Christ is the founder of Cf Port GmbH.
He currently holds the position of Chief Financial Officer at Immatics Biotechnologies GmbH and Immatics NV.
Previously, he served as Finance Director at Avery Dennison Corp., Hoechst AG, and Avery Dennison GmbH.
He also held the role of Chief Financial Officer at MediGene AG, Vivoryon Therapeutics NV, NovImmune SA, Proteros biostructures GmbH, and EleGene AG.
Additionally, he was the Chief Financial Officer at InflaRx NV until 2020.
Mr. Christ has also served as a Member-Supervisory Board at Immunocore Holdings Plc.
He obtained an MBA from Boston University and Wuerzburg Schweinfurt University of Applied Sciences.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMATICS N.V.
0.16% | 30/01/2024 | 169,907 ( 0.16% ) | 2 M $ | 30/03/2024 |
Arnd Christ active positions
| Companies | Position | Start |
|---|---|---|
| IMMATICS N.V. | Director of Finance/CFO | 30/09/2020 |
| Cf Port GmbH | Founder | - |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Director of Finance/CFO | 31/12/2019 |
Former positions of Arnd Christ
| Companies | Position | End |
|---|---|---|
| INFLARX N.V. | Director of Finance/CFO | 30/09/2020 |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Director of Finance/CFO | 31/12/2013 |
| MEDIGENE AG | Director of Finance/CFO | 18/09/2012 |
| NOVIMMUNE SA | Director of Finance/CFO | 31/12/2009 |
| VIVORYON THERAPEUTICS N.V. | Director of Finance/CFO | 31/12/2006 |
Training of Arnd Christ
| Boston University | Masters Business Admin |
| Wuerzburg Schweinfurt University of Applied Sciences | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| AVERY DENNISON CORPORATION | Process Industries |
| MEDIGENE AG | Health Technology |
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| INFLARX N.V. | Health Technology |
| IMMATICS N.V. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Private companies | 7 |
|---|---|
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Novimmune SA
 Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
Proteros biostructures GmbH
Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Health Services |
| EleGene AG | |
| Cf Port GmbH | |
| Avery Dennison GmbH |
- Stock Market
- Insiders
- Arnd Christ
